ABCAM
LIVE

Serial Number

79308302

Owner

ABCAM LIMITED

Attorney

Christopher M. Kindel

Filing Date

Jul 27, 2020

Add to watchlist:

No watchlists yet
View on USPTO

ABCAM Trademark

Serial Number: 79308302 • Registration: 6709014

ABCAM is a trademark filed by ABCAM LIMITED on July 27, 2020. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics). The application is currently registered and active.

Owner Contact Info

ABCAM LIMITED (12 trademarks)

DISCOVERY DRIVE
CAMBRIDGE CB2 0AX , GB

Entity Type: 24

ABCAM PLC (29 trademarks)

Discovery Drive
Cambridge CB2 0AX

Entity Type: 11

Trademark Details

Filing Date

July 27, 2020

Registration Date

April 26, 2022

Published for Opposition

February 8, 2022

Goods & Services

Downloadable computer software for operating scientific and laboratory apparatus and instruments; downloadable computer software for detecting, identifying, reading, quantifying, decoding, tracking or analyzing nucleic acids, proteins, cells, molecules or encoded particles, and for processing, managing, tracking displaying, and creating reports of generated data; downloadable computer software for scientific, laboratory, clinical or medical analysis of cells, molecules or encoded particles; none of the aforesaid including microscope adapters

Medical diagnostic preparations and materials in the nature of substances, reagents and assays; diagnostic kits for single- and multi-plexed detection, quantification or identification consisting primarily of biological molecules, proteins, nucleic acids and small molecules for medical or clinical use, namely, for use in disease testing; diagnostic kits consisting primarily of reagents, particles, vials and buffers for medical or clinical use, namely, for use in disease testing; medical diagnostic assays for monitoring, identifying, detecting, or quantifying biological molecules or small molecules for medical or clinical use, namely, for use in disease testing; diagnostic kits consisting primarily of reagents, particles, vials and buffers for monitoring, identifying, detecting, or quantifying biological molecules or small molecules for medical or clinical use, namely, for use in disease testing; medical diagnostic single- and multi-plexed assays for analysis of proteins, nucleic acids and small molecules for medical or clinical use, namely, for use in disease testing

Filing History

CHANGE OF NAME/ADDRESS REC'D FROM IB
Sep 20, 2024 ADCH
FINAL DECISION TRANSACTION PROCESSED BY IB
Sep 26, 2022 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Sep 1, 2022 FICS
FINAL DISPOSITION PROCESSED
Sep 1, 2022 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jul 26, 2022 FICR
REGISTERED-PRINCIPAL REGISTER
Apr 26, 2022 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 8, 2022 NPUB
PUBLISHED FOR OPPOSITION
Feb 8, 2022 PUBO
NOTIFICATION PROCESSED BY IB
Feb 6, 2022 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 19, 2022 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jan 19, 2022 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 19, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 5, 2022 CNSA
ASSIGNED TO EXAMINER
Jan 4, 2022 DOCK
EXAMINER'S AMENDMENT ENTERED
Nov 10, 2021 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Nov 10, 2021 GNEN
EXAMINERS AMENDMENT E-MAILED
Nov 10, 2021 GNEA
EXAMINERS AMENDMENT -WRITTEN
Nov 10, 2021 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 21, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 21, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 21, 2021 TROA
REFUSAL PROCESSED BY IB
May 12, 2021 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Apr 22, 2021 RFCS
REFUSAL PROCESSED BY MPU
Apr 22, 2021 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Apr 16, 2021 RFCR
APPLICATION FILING RECEIPT MAILED
Apr 16, 2021 MAFR
NON-FINAL ACTION WRITTEN
Apr 15, 2021 CNRT
ASSIGNED TO EXAMINER
Apr 12, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 12, 2021 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Apr 10, 2021 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Apr 8, 2021 REPR